Silexion Therapeutics (NASDAQ:SLXN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Silexion Therapeutics (NASDAQ:SLXN – Free Report) to a hold rating in a research note issued to investors on Saturday,Wall Street Zen reports.

A number of other equities analysts have also commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Friday, September 11th. Maxim Group lowered Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

View Our Latest Stock Analysis on Silexion Therapeutics

Silexion Therapeutics Price Performance

SLXN opened at $1.76 on Friday. The business has a 50 day moving average of $5.57 and a 200-day moving average of $137.78. Silexion Therapeutics has a 1-year low of $1.74 and a 1-year high of $777.12.

Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($13.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($218.40) by $204.70. Equities research analysts predict that Silexion Therapeutics will post -112.71 earnings per share for the current fiscal year.

Silexion Therapeutics Company Profile

(Get Free Report)

Silexion Therapeutics is an Israel-based clinical-stage biotechnology company developing RNA interference (RNAi) treatments for cancers associated with mutations in the KRAS gene. Its approach is designed to reduce the activity of cancer-related genes rather than target tumors with conventional drug therapies. The company’s lead candidate, SIL-204, is being developed for pancreatic cancer. It is an investigational treatment, and Silexion has not established a commercial product portfolio. Silexion’s work is focused on research and clinical development; its treatments are not approved for routine commercial use.

Further Reading

Receive News & Ratings for Silexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.